IKT - Inhibikase Therapeutics Inc
IEX Last Trade
1.39
0.003 0.252%
Share volume: 3,098
Last Updated: Fri 30 Aug 2024 08:39:54 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.39
0.00
0.25%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-12 | 2022-11-14 | 2023-03-31 | 2023-05-15 | 2023-08-14 | 2023-11-14 | 2024-03-27 | 2024-05-15 | |
| Total revenue | 6.552 K | 7.291 K | 63.566 K | 64.521 K | 116.410 K | 79.569 K | 1.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 6.552 K | 7.291 K | 63.566 K | 64.521 K | 116.410 K | 79.569 K | 1.000 | 0.000 | |
| 11.28% | 771.84% | 1.50% | 80.42% | -31.65% | -100.00% | -100.00% | |||
| Operating expenses | 4.646 M | 4.520 M | 4.399 M | 4.779 M | 6.319 M | 4.848 M | 4.404 M | 4.782 M | |
| Selling general and admin | 1.664 M | 1.539 M | 1.344 M | 1.925 M | 1.783 M | 1.623 M | 1.401 M | 2.031 M | |
| Research and development | 2.982 M | 2.982 M | 3.054 M | 2.854 M | 4.536 M | 3.226 M | 3.003 M | 2.751 M | |
| Total expenses | 4.646 M | 4.520 M | 4.399 M | 4.779 M | 6.319 M | 4.848 M | 4.404 M | 4.782 M | |
| -2.71% | -2.70% | 8.66% | 32.21% | -23.27% | -9.18% | 8.60% | |||
| Operating income | -4.640 M | -4.513 M | -4.335 M | -4.715 M | -6.202 M | -4.769 M | -4.404 M | -4.782 M | |
| Ebit | -4.640 M | -4.513 M | -4.335 M | -4.715 M | -6.202 M | -4.769 M | -4.404 M | -4.782 M | |
| Pretax income | -4.640 M | -4.495 M | -4.279 M | -4.478 M | -5.778 M | -4.595 M | -4.178 M | -4.650 M | |
| -3.13% | -4.79% | 4.64% | 29.04% | -20.47% | -9.08% | 11.29% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -4.640 M | -4.495 M | -4.279 M | -4.478 M | -5.778 M | -4.595 M | -4.178 M | -4.650 M | |
| 3.13% | 4.79% | -4.64% | -29.04% | 20.47% | 9.08% | -11.29% | |||
| Net income | -4.640 M | -4.495 M | -4.279 M | -4.478 M | -5.778 M | -4.595 M | -4.178 M | -4.650 M | |
| 3.13% | 4.79% | -4.64% | -29.04% | 20.47% | 9.08% | -11.29% |